Hexanoyl Dipeptide-3 Norleucine Acetate
Hexanoyl-Arg-Ala-Nle-NH2 acetate, a cosmetic peptide salt. PubMed holds no study of it.
Hexanoyl dipeptide-3 norleucine acetate is the acetate salt of hexanoyl-Arg-Ala-norleucinamide (PubChem's record, under its INCI name). It is sold as a skin-care ingredient, but a title-and-abstract search of PubMed for its INCI name finds no study of it. It is not a drug.
No dosing data yet Details ↓
Recommended Dosing
No dosing data yet
This page has no dosing data yet.
Mechanism of action
Not established: no published study describes its action.
Primary uses
- Cosmetic skin-care formulations
Typical dosing
No published study states an amount of this ingredient used on skin, and a supplier's use level is not a source on this site, so none is given.
Regulatory status
Not a drug: PubChem lists it under its INCI name as a cosmetic ingredient (CID 71587827). Drugs@FDA and the EMA medicines list hold no record for it (searched October 28, 2026).
Status as of this entry's last review, October 28, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.
What we checked
Hexanoyl Dipeptide-3 Norleucine Acetate is a cosmetic peptide ingredient with little or no published literature; this section records what can be checked.
Identity, computed
| Structure | N2-hexanoyl-Arg-Ala-Nle-NH2, as the acetate salt (PubChem's IUPAC name, CID 71587827) |
| Formula | C23H45N7O6 including one acetic acid (PubChem) |
| Molecular weight | 515.6 g/mol including the acetate (PubChem) |
PubChem records the ingredient as a 1:1 acetate salt, and the calculator used elsewhere on this site does not handle the hexanoyl cap, so the formula and weight are PubChem's, salt included.
Regulatory status, read October 28, 2026
Drugs@FDA: 0 records for “hexanoyl dipeptide-3 norleucine acetate”. EMA medicines list: 0 records for “hexanoyl dipeptide-3 norleucine acetate”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 80 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on October 28, 2026.
What we looked for and did not find
No published study of any kind, no registry record and no drug approval.
| Source | Query | Results, October 28, 2026 | What it was |
|---|---|---|---|
| PubMed | ("dipeptide-3"[tiab] AND hexanoyl[tiab]) | 0 | name matched word by word |
| ClinicalTrials.gov | hexanoyl dipeptide-3 norleucine acetate | 0 | |
| Drugs@FDA (openFDA) | hexanoyl dipeptide-3 norleucine acetate | 0 | |
| EMA medicines list | hexanoyl dipeptide-3 norleucine acetate | 0 |
References
- [other] PubChem CID 71587827, Hexanoyl Dipeptide-3 Norleucine Acetate: formula C23H45N7O6, molecular weight 515.6. Read October 28, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/71587827
Related peptides
Guides & tools
Explore with tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.